STOK Stoke Therapeutics, Inc.

NASDAQ

$27.21

Stoke Therapeutics, Inc. (STOK) is expected to report earnings on January 28, 2027, after the market close. The consensus earnings estimate is a loss of $1.10 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +4.5% since its last earnings release on October 29, 2026.

Stoke Therapeutics Missed Consensus Estimates

Thursday, October 29, 2026 · 4:01 PM ET

4th Quarter, Dec 2026

Thursday · 4:00 PM ET

Earnings Whisper

-

vs ($1.10)

Rev est $9.05M

Volatility

Enter your expectations below to reveal the current volatility.

Trend Analysis

Expectation

Earnings

Price action

Signals

Score

Sentiment

Grade

Life Cycle

Call Analysis

Earnings-AVWAP $26.75

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Stoke Therapeutics, Inc.

Stoke Therapeutics is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine.

Sector

Healthcare

Industry

Biotechnology

Held By 2 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.